Vivo Capital LLC Decreases Stock Position in Delcath Systems, Inc. (NASDAQ:DCTH)

Vivo Capital LLC lowered its stake in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 53.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 855,191 shares of the company's stock after selling 1,000,000 shares during the period. Vivo Capital LLC owned approximately 3.88% of Delcath Systems worth $3,558,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in DCTH. Levin Capital Strategies L.P. bought a new position in shares of Delcath Systems in the 3rd quarter valued at approximately $162,000. Stonepine Capital Management LLC raised its position in shares of Delcath Systems by 81.2% in the third quarter. Stonepine Capital Management LLC now owns 686,240 shares of the company's stock valued at $2,779,000 after purchasing an additional 307,453 shares during the period. Armistice Capital LLC acquired a new stake in shares of Delcath Systems in the third quarter worth $664,000. Finally, WealthPlan Investment Management LLC bought a new stake in shares of Delcath Systems during the 4th quarter worth $73,000. Institutional investors own 61.12% of the company's stock.

Delcath Systems Trading Up 0.8 %

DCTH traded up $0.04 on Thursday, hitting $5.56. 153,586 shares of the stock traded hands, compared to its average volume of 220,740. The business has a fifty day moving average price of $4.75 and a two-hundred day moving average price of $4.08. Delcath Systems, Inc. has a 52 week low of $2.25 and a 52 week high of $7.99. The firm has a market capitalization of $154.46 million, a PE ratio of -1.87 and a beta of 0.55.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its earnings results on Tuesday, March 26th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.19. Delcath Systems had a negative return on equity of 563.60% and a negative net margin of 2,308.86%. The firm had revenue of $0.54 million during the quarter, compared to analysts' expectations of $0.48 million. During the same period last year, the business earned ($0.86) earnings per share. On average, equities research analysts forecast that Delcath Systems, Inc. will post -1.45 EPS for the current fiscal year.

Analyst Ratings Changes

DCTH has been the subject of a number of research analyst reports. StockNews.com raised shares of Delcath Systems to a "sell" rating in a research report on Wednesday, March 27th. HC Wainwright raised their target price on Delcath Systems from $18.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, Delcath Systems presently has an average rating of "Moderate Buy" and a consensus target price of $18.50.

Insider Buying and Selling

In other news, Director Gil Aharon purchased 26,882 shares of Delcath Systems stock in a transaction on Tuesday, March 19th. The shares were purchased at an average cost of $3.72 per share, for a total transaction of $100,001.04. Following the completion of the transaction, the director now directly owns 1,069,710 shares in the company, valued at $3,979,321.20. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 17.94% of the stock is currently owned by corporate insiders.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.